1-3 of 3
Gordon Dewald, Ph.D.
Close
Sort by
Journal Articles

Gene Dosage of the Cell Cycle Regulatory Phosphatases Cdc25C and PP2A Determines Sensitivity to Lenalidomide in del(5q) MDS.

Sheng Wei, MD, Kathy Rocha, BS, Ann Williams, Ph.D., Xianhong Chen, Ph.D, P.K. Burnette, Ph.D., Julie Y. Djeu, Ph.D., Qing Liu, Ph.D., John Byrd, M.D., Lubomir Sokol, M.D., Nick Lawrence, Ph.D., Roberta Pireddu, Ph.D, Gordon Dewald, Ph.D., Jaroslaw Maciejewski, M.D., Alan List, M.D.
Journal: Blood
Blood (2007) 110 (11): 118.
https://doi.org/10.1182/blood.V110.11.118.118
Published: 2007
Journal Articles

Efficacy of Conventional Cytogenetics and FISH for EGR1 To Detect Deletion 5q in Hematological Disorders and To Assess Response to Treatment with Lenalidomide.

Ying Zou, MD, Stephanie Fink, Kimberly Stockero, Sarah Paternoster, Stephanie Smoley, Han Tun, M.D., Craig Reeder, M.D., Ayalew Tefferi, M.D., Gordon Dewald, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2351.
https://doi.org/10.1182/blood.V108.11.2351.2351
Published: 2006
Journal Articles

Clinical Significance of Homozygous D13S319 Deletion in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Stephanie Fink, Susan Geyer, Ph.D., Tait Shanafelt, M.D., Stephanie Smoley, Sarah Paternoster, Karin Giordano, Renee Tschumper, Diane Jelinkek, Ph.D., Nancy Bone, Brian Kabat, Timothy Call, M.D., Robert Phyliky, M.D., Neil Kay, M.D., Gordon Dewald, Ph.D
Journal: Blood
Blood (2004) 104 (11): 2799.
https://doi.org/10.1182/blood.V104.11.2799.2799
Published: 2004